Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2026 11:15 ET | Source: Spherix Global Insights

CTD-ILD Enters New Treatment Era, but Physicians Still See Significant Unmet Need

Exton, PA, June 17, 2026 (GLOBE NEWSWIRE) -- Despite the introduction of new therapies, connective tissue disease-associated interstitial lung disease (CTD-ILD) remains an area of significant unmet...
May 22, 2026 08:15 ET | Source: Boehringer Ingelheim Limited

CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU

Not intended for US and UK media Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are life-threatening, progressive lung conditions that require early and sustained...
May 18, 2026 02:00 ET | Source: Boehringer Ingelheim Limited

JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment

Not intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary...
December 19, 2025 15:10 ET | Source: Boehringer Ingelheim Limited

U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults

Not intended for UK audiences Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2Affecting up to 100,000...
December 10, 2025 05:35 ET | Source: Boehringer Ingelheim Limited

JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five years.PPF is a rare lung condition, more life-threatening than many...